Kakyung Kim

Archives
Log in
Subscribe
October 28, 2026

๐Ÿ“ˆ econ-radar 2026-10-28 ยท AI ์„ค๋น„ํˆฌ์ž(capital expenditure)์™€ ROI

๐Ÿ“ˆ econ-radar 2026-10-28 ยท AI ์„ค๋น„ํˆฌ์ž(capital expenditure)์™€ ROI

๐Ÿ“ˆ econ-radar ๋ฐ์ผ๋ฆฌ

2026-10-28

์ œ์•ฝยท๋ฐ”์ด์˜คยทAI์— ๋ฌด๊ฒŒ๋ฅผ ๋‘” ๊ฒฝ์ œ ๋ฐ์ผ๋ฆฌ โ€” ์‚ฐ์—…๊ตฌ์กฐยทํˆฌ์žยท์‹œ์žฅ 3๋ Œ์ฆˆ

At a Glance

๐Ÿงฌ ESMO 2026์—์„œ sac-TMT ๋‹จ์ผ ADC ํ”Œ๋žซํผ์ด ์ž๊ถ๋‚ด๋ง‰์•”ยทNSCLC ๋ณต์ˆ˜ Phase 3๋ฅผ ์™„๊ฒฐํ–ˆ๊ณ , B7-H3 ADC๋Š” ์†Œ์•„ยท์ฒญ์†Œ๋…„ ๊ณ ํ˜•์•”์— ์ฒซ Phase 3 ์–‘์„ฑ์„ ๋ƒˆ๋‹ค.

๐Ÿค– ์˜ค๋Š˜ ๋ฐค(ํ•œ๊ตญ ์‹œ๊ฐ„ 10/29 ์ƒˆ๋ฒฝ) FOMC ๋™๊ฒฐ ๊ฒฐ์ •ยทAlphabet Q3ยทMicrosoft FY27 Q1์ด ๋™์‹œ์— ๋ฐœํ‘œ๋œ๋‹ค. ์ˆ˜๋ฐฑ์กฐ ์› AI ์„ค๋น„ํˆฌ์ž๊ฐ€ ํด๋ผ์šฐ๋“œ ๋งค์ถœ๋กœ ๋Œ์•„์˜ค๋Š”์ง€ ์ฒ˜์Œ์œผ๋กœ ๊ณต์‹ ์ˆ˜์น˜๊ฐ€ ํ™•์ธ๋œ๋‹ค.

๐Ÿ’ฐ ๋‚ด์ผ(10/29) SKํ•˜์ด๋‹‰์Šคยท์‚ผ์„ฑ์ „์ž Q3 ์‹ค์ ์ด ํ•จ๊ป˜ ๋‚˜์˜จ๋‹ค. HBM4(๊ณ ๋Œ€์—ญํญ๋ฉ”๋ชจ๋ฆฌ 4์„ธ๋Œ€) ๋งค์ถœ์ด ์ฒ˜์Œ์œผ๋กœ ์žฌ๋ฌด์— ๋ฐ˜์˜๋˜๋Š” ๋ถ„๊ธฐ๋‹ค.

Today's Top 5

Bio

1. OptiTROP-Lung06 โ€” PD-L1 ์Œ์„ฑ NSCLC 1์ฐจ ์น˜๋ฃŒ, ADC+ICI ๋ณ‘ํ•ฉ ์ฒซ Phase 3 ์–‘์„ฑ

sac-TMT(sacituzumab tirumotecan, ์‚ฌํฌ์ดํˆฌ์ฃผ๋ง™ ํ‹ฐ๋ฃจ๋ชจํ…Œ์นธ)+pembrolizumab์ด PD-L1 TPS <1% ์ง„ํ–‰์„ฑ ๋น„ํŽธํ‰ ๋น„์†Œ์„ธํฌํ์•”(nsq-NSCLC) 1์ฐจ ์น˜๋ฃŒ์—์„œ ๋ฐฑ๊ธˆ ํ™”ํ•™์š”๋ฒ•+pembrolizumab ๋Œ€๋น„ ๋ฌด์ง„ํ–‰์ƒ์กด๊ธฐ๊ฐ„(PFS) ์œ„ํ—˜์„ 51% ๋‚ฎ์ท„๋‹ค(HR ~0.49, ์ค‘์•™ 15.0๊ฐœ์›” vs 5.7๊ฐœ์›”). NEJM์— ๋™์‹œ ๊ฒŒ์žฌ๋๋‹ค. ์ „์ฒด์ƒ์กด๊ธฐ๊ฐ„(OS)์€ ๋ฏธ์„ฑ์ˆ™์œผ๋กœ ํ†ต๊ณ„์  ์œ ์˜์„ฑ์„ ์ถฉ์กฑํ•˜์ง€ ๋ชปํ–ˆ์œผ๋‚˜ "42% ๊ฐœ์„  ๊ฒฝํ–ฅ"์ด ๊ด€์ฐฐ๋๋‹ค.

โ†— Pharmaphorum

Bio

2. TroFuse-005 โ€” ์ž๊ถ๋‚ด๋ง‰์•” 2์ฐจ+ OS 6.9๊ฐœ์›” ์—ฐ์žฅ, PDUFA 2027/6/15

sac-TMT๊ฐ€ ์ž๊ถ๋‚ด๋ง‰์•”(endometrial cancer) 2์ฐจ ์ด์ƒ ์น˜๋ฃŒ(N=776)์—์„œ ๋…์†Œ๋ฃจ๋น„์‹  ๋˜๋Š” ํŒŒํด๋ฆฌํƒ์…€(์˜์‚ฌ ์„ ํƒ) ๋Œ€๋น„ OS ์ค‘์•™๊ฐ’์„ 19.0๊ฐœ์›” ๋Œ€ 12.1๊ฐœ์›”๋กœ ๋Š˜๋ ธ๋‹ค(HR 0.68, p<0.0001). PFS HR 0.59, ORR 35.1% ๋Œ€ 17.3%๋‹ค(๋ณธ๋ฌธ ํ™•์ธ ํ•„์š”). The Lancet์— ๋™์‹œ ๊ฒŒ์žฌ๋์œผ๋ฉฐ FDA Priority Review๊ฐ€ ์ง„ํ–‰ ์ค‘์ด๋‹ค(PDUFA 2027๋…„ 6์›” 15์ผ, ๋ณธ๋ฌธ ํ™•์ธ ํ•„์š”).

โ†— BioPharm International

AIMacro

3. FOMC + Alphabet + Microsoft ํŠธ๋ฆฌํ”Œ ์ด๋ฒคํŠธ โ€” AI capex ROI ์ฒซ ๊ณต์‹ ์ฑ„์ 

์˜ค๋Š˜(ํ•œ๊ตญ ์‹œ๊ฐ„ 10/29 03:00) FOMC๊ฐ€ ํ˜„ํ–‰ 3.75~4.00% ๊ธˆ๋ฆฌ๋ฅผ ๋™๊ฒฐํ•  ํ™•๋ฅ ์ด ์•ฝ 90%๋กœ ๋ฐ˜์˜๋ผ ์žˆ๋‹ค. ๊ฐ™์€ ๋‚  ์ €๋… Alphabet Q3(Google Cloud ์ปจ์„ผ์„œ์Šค ์•ฝ 290์–ต๋‹ฌ๋Ÿฌ(์•ฝ 40์กฐ์›, ๋ณธ๋ฌธ ํ™•์ธ ํ•„์š”), YoY ~100% ๊ธฐ๋Œ€)์™€ Microsoft FY2027 Q1(Azure 44~45% CC ์„ฑ์žฅ ๊ฐ€์ด๋˜์Šค, AI ์—ฐ๊ฐ„ ๋Ÿฐ๋ ˆ์ดํŠธ 370์–ต๋‹ฌ๋Ÿฌ(์•ฝ 51์กฐ3,000์–ต์›))์ด ๋ฐœํ‘œ๋œ๋‹ค. Meta๊ฐ€ 2026 ์„ค๋น„ํˆฌ์ž(capex)๋ฅผ 1,350~1,450์–ต๋‹ฌ๋Ÿฌ(์•ฝ 187์กฐ~201์กฐ์›)๋กœ ๊ณต์–ธํ•œ ์ดํ›„ AI ํˆฌ์ž ์ˆ˜์ต์„ฑ ๋…ผ์Ÿ์ด ๊ณต๋ก ํ™”๋์œผ๋ฉฐ, ์˜ค๋Š˜ ๋ฐค์ด ๊ทธ ์ฒซ ๊ณต์‹ ๋‹ต์•ˆ ๋‚ ์ด๋‹ค.

โ†— MarketBeat Alphabet ์ปจ์„ผ์„œ์Šค

Semiconductor

4. SKํ•˜์ด๋‹‰์Šคยท์‚ผ์„ฑ์ „์ž Q3 โ€” HBM4 ์ฒซ ๋งค์ถœ ๋ฐ˜์˜ ๋ถ„๊ธฐ

SKํ•˜์ด๋‹‰์Šค(000660.KS) Q3 FnGuide ์ปจ์„ผ์„œ์Šค ์˜์—…์ด์ต 76์กฐ9,600์–ต์›(OPM ~78.4%), ์‚ผ์„ฑ์ „์ž(005930.KS) Q3 ์ž ์ • ์˜์—…์ด์ต 107์กฐ4,000์–ต์›(YoY +782.5%)์ด ๋‚ด์ผ(10/29) ๋‚˜๋ž€ํžˆ ๊ณต๊ฐœ๋œ๋‹ค. HBM4๊ฐ€ Nvidia GB300 ์„œ๋ฒ„๋ฅผ ํ†ตํ•ด ์ฒ˜์Œ์œผ๋กœ ์žฌ๋ฌด์— ๋ฐ˜์˜๋˜๋Š” ๋ถ„๊ธฐ๋‹ค. Counterpoint Q2 ๊ธฐ์ค€ HBM ์ ์œ ์œจ์€ SKํ•˜์ด๋‹‰์Šค 50%ยท์‚ผ์„ฑ์ „์ž 33%ยทMicron 18%์˜€๋‹ค.

โ†— TrendForce ์‚ผ์„ฑ ์ž ์ •์‹ค์ 

Bio

5. ARTEMIS-011 โ€” B7-H3 ADC ๊ณจ์œก์ข… Phase 3, PFS HR 0.33

GSKยทHansoh์˜ ๋ฆฌ์Šค๋ถ€ํƒ€ํˆฌ๊ทธ ๋ ˆ์ œํ…Œ์นธ(risvutatug rezetecan, Ris-Rez) ARTEMIS-011 Phase 3(N=122)์ด ์žฌ๋ฐœยท๋ถˆ์‘ ๊ณจ์œก์ข…(osteosarcoma) 2์ฐจ ์ด์ƒ ์น˜๋ฃŒ์—์„œ ์ค‘์•™ PFS 5.5๊ฐœ์›” ๋Œ€ ์ ฌ์‹œํƒ€๋นˆ+๋„์„ธํƒ์…€ 1.4๊ฐœ์›”์„ ๊ธฐ๋กํ–ˆ๋‹ค(HR 0.33, p<0.0001). ORR 15% ๋Œ€ 2%, DCR 76% ๋Œ€ 33%๋‹ค. OS HR 0.51(๋ฏธ์„ฑ์ˆ™)(๋ณธ๋ฌธ ํ™•์ธ ํ•„์š”). FDA BTD(ํš๊ธฐ์ ์น˜๋ฃŒ์ œ์ง€์ •)ยทEMA PRIMEยท๊ธ€๋กœ๋ฒŒ ํฌ๊ท€์˜์•ฝํ’ˆ ์ง€์ •์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ๋‹ค.

โ†— KolPulse ARTEMIS-011

๐Ÿ—ฃ ์˜ค๋Š˜์˜ ํ™”์ œ

AI capex ROI๋Š” ์ˆ˜๋ฐฑ์กฐ ์›์˜ ๋ฐ์ดํ„ฐ์„ผํ„ฐ ํˆฌ์ž๊ฐ€ ํด๋ผ์šฐ๋“œ ๋งค์ถœ ์„ฑ์žฅ์œผ๋กœ ์–ผ๋งˆ๋‚˜ ๋น ๋ฅด๊ฒŒ ํšŒ์ˆ˜๋˜๋Š”์ง€ ๋ณด์—ฌ์ฃผ๋Š” ์ง€ํ‘œ๋‹ค. ์˜ค๋Š˜ ๋ฐค AlphabetยทMicrosoft Q3๊ฐ€ ๊ทธ ์ฒซ ๋ฒˆ์งธ ๊ณต์‹ ์ฑ„์ ํ‘œ๋‹ค.

์ „์ฒด ๋ฆฌํฌํŠธ ๋ณด๊ธฐ โ†’

Deep Dive ยท Demand ยท Investment ยท Companies ยท Sources ์ „์ฒด๋Š” ์œ„ ๋งํฌ์—์„œ ๋ณด์‹ค ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

ํ…”๋ ˆ๊ทธ๋žจ @econradar ๋กœ๋„ ๋ฐ›๊ธฐ

econ-radar ยท 2026-10-28

ํˆฌ์ž ์ฐธ๊ณ ์šฉ ์ •๋ณด์ž…๋‹ˆ๋‹ค. ์ตœ์ข… ํŒ๋‹จ๊ณผ ์ฑ…์ž„์€ ๋ณธ์ธ์—๊ฒŒ ์žˆ์Šต๋‹ˆ๋‹ค.

Don't miss what's next. Subscribe to Kakyung Kim:
โ† Newer ๐Ÿ“ˆ econ-radar 2026-10-29 ยท Anthropic IPO: ์ƒ์„ฑํ˜• AI ๊ธฐ์—…์ด ๊ณต๊ฐœ์‹œ์žฅ์— ์ฒ˜์Œ ์„œ๋Š” ๋‚  Older โ†’ ๐Ÿ“ˆ econ-radar 2026-10-27 ยท ESMO 2026 ADC ๊ฒฐ์‚ฐ: ๋ฐ”์ด์˜ค๋งˆ์ปค๊ฐ€ ์Šน๋ถ€๋ฅผ ๊ฐ€๋ฅธ๋‹ค
Powered by Buttondown, the easiest way to start and grow your newsletter.